Biotech IPOs Get Bigger, But Not Necessarily Better

The first $1bn quarter since 2021 suggests that biotech’s IPO window is opening once more. But times remain tough, and many recently listed groups have seen their valuations fall.  

Initial Public Offering IPO Stock Market Ticker

Biopharma is going public again. That is the unmistakable trend throughout the year so far – indeed it has been clear since the spring of 2022. And the third quarter has seen the most cash raised by floating biotech companies since the end of 2021, totalling $1.3bn.

Key Takeaways
  • Eight biopharma IPOs raised a total of $1.3bn in Q3 2023

This is a rosy picture until you look at how these companies have done on the stock markets since their...

More from Business

More from Scrip